BioNova is a biotech company that develops precision drugs for major disease areas. By utilizing and building on its focus in the field of nuclear receptors and preclinical drug discovery, it could become a successful intermediary firm competing with Big Pharma – if the right strategic decisions are taken.

BioNova is also a fictitious case study that allows both students and teachers to become immersed in a venture capital based enterprise and to experience the vibrant challenge of burning issues in preparing acquisitions of licenses, discussing and realizing strategies, and resolving financial crises. The case study is designed for courses at schools of business, industrial management and biotech entrepreneurship.

Included in the book is an English-Swedish glossary of common business terms, five areas for discussion and three in-depth assignments that function well in exercises and seminars. As a whole, the case study can thus help both students and teachers to learn to understand and discuss strategic issues confronting managers in contemporary biotech companies.